BLI-800-301: BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00503607
Recruitment Status : Completed
First Posted : July 19, 2007
Last Update Posted : December 27, 2007
Information provided by:
Braintree Laboratories

Brief Summary:
This is a randomized, parallel, multi-center, single-blind study, comparing BLI-800 to an FDA approved bowel preparation in adult subjects undergoing colonoscopy.

Condition or disease Intervention/treatment Phase
Colonoscopy Drug: BLI-800 Drug: Polyethylene glycol 3350 based bowel preparation Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single
Official Title: A Safety and Efficacy Evaluation of BLI-800 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
Study Start Date : July 2007
Actual Primary Completion Date : November 2007
Actual Study Completion Date : November 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Colonoscopy

Primary Outcome Measures :
  1. Efficacy - preparation quality using a 4 point scale [ Time Frame: 2-Day ]

Secondary Outcome Measures :
  1. Safety - preparation related side effects; laboratory analysis [ Time Frame: 30-Day ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication, including:

    • Evaluation of BE results
    • GI bleeding
    • Anemia of unknown etiology
    • Neoplastic disease surveillance
    • Endosonography
    • Inflammatory bowel disease
    • Unknown diarrhea or constipation etiology
    • Polypectomy
    • Laser therapy
    • Routine Screening
  • At least 18 years of age
  • Otherwise in good health, as determined by physical exam and medical history
  • If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, depot contraceptive, abstinent, or vasectomized spouse)
  • Negative urine pregnancy test at screening, if applicable
  • In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study

Exclusion Criteria:

  • Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon.
  • Subjects with impaired consciousness that predisposes them to pulmonary aspiration.
  • Subjects who are undergoing colonoscopy for foreign body removal and decompression.
  • Subjects with clinically significant electrolyte abnormalities based on Visit 1 laboratory results, such as hypernatremia, hyponatremia, hyperphosphatemia, hypokalemia, hypocalcemia, dehydration, or those secondary to the use of diuretics or angiotensin converting enzyme (ACE) inhibitors.
  • Subjects with a history of renal or hepatic insufficiency or congestive heart failure.
  • Subjects who had previous gastrointestinal surgeries
  • Subjects who are pregnant or lactating, or intending to become pregnant during the study.
  • Subjects of childbearing potential who refuse a pregnancy test.
  • Subjects who are allergic to any preparation components
  • Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures.
  • Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00503607

United States, Alabama
Mobile, Alabama, United States, 36693
United States, District of Columbia
Washington, District of Columbia, United States, 20010
United States, Florida
Jupiter, Florida, United States, 33458
Miami, Florida, United States, 33143
New Smyrna Beach, Florida, United States, 32168
United States, Louisiana
Monroe, Louisiana, United States, 71201
United States, Maryland
Laurel, Maryland, United States, 20707
United States, New York
Great Neck, New York, United States, 11023
United States, North Carolina
Raleigh, North Carolina, United States, 27612
United States, Pennsylvania
Lancaster, Pennsylvania, United States, 17604
United States, Virginia
Chesapeake, Virginia, United States, 23320
Sponsors and Collaborators
Braintree Laboratories
Study Director: John D McGowan, BS Braintree Laboratories, Inc.

Responsible Party: John McGowan, Clinical Operations Manager, Braintree Laboratories, Inc. Identifier: NCT00503607     History of Changes
Other Study ID Numbers: BLI-800-301
First Posted: July 19, 2007    Key Record Dates
Last Update Posted: December 27, 2007
Last Verified: December 2007

Keywords provided by Braintree Laboratories:
bowel preparation

Additional relevant MeSH terms:
Polyethylene glycol 3350
Gastrointestinal Agents